Morningstar
•
Jun 23, 2026
BridgeBio Pharma, Inc.: BridgeBio Earnings: Strong Sales of Attruby and Advancing Pipeline Support Positive Outlook
Summary
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene
Upgrade to begin using premium research reports and get so much more.
Exclusive reports, detailed company profiles, and best-in-class trade insights to take your portfolio to the next level
UpgradeRelated Reports
ROIV: Lowering target price to $36.00
Sep 02, 2026
•
ROIV
KRYS: Raising target price to $400.00
Sep 02, 2026
•
KRYS
CYTK: Lowering target price to $75.00
Sep 02, 2026
•
CYTK
PTGX: Lowering target price to $154.00
Sep 02, 2026
•
PTGX
ROIV: Lowering target price to $38.00
Aug 26, 2026
•
ROIV
